SCHEMBL6730191

SCHEMBL6730191

O=C(c1ncc(-c2ccccn2)nn1)N1CCN(S(=O)(=O)c2nc3cc(Cl)ccc3[nH]2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
PKM P14618 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
F10 P00742 3/20 0.39
GRM5 P41594 1/20 0.39
GAA P10253 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TACR3 P29371 1/20 0.38
OPRM1 P35372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6730185 0.93 METAP2 (0.44) ALDH1A1PKMRXFP1HPGDHSD17B10
SCHEMBL6730406 0.90 ALDH1A1 (0.43) ALDH1A1PKMRXFP1HPGDHSD17B10
SCHEMBL6732125 0.88 ALDH1A1 (0.45) ALDH1A1HPGDPOLBMAPTKMT2A
SCHEMBL6730053 0.87 ALDH1A1 (0.44) ALDH1A1PKMRXFP1HPGDHSD17B10
SCHEMBL6735897 0.87 ALDH1A1 (0.44) ALDH1A1PKMRXFP1HPGDHSD17B10
SCHEMBL6730884 0.86 F10 (0.54) ALDH1A1PKMRXFP1F10GRM5
SCHEMBL6731480 0.86 GAA (0.36) MEN1KMT2ALMNAL3MBTL1F10
SCHEMBL6726550 0.85 LMNA (0.45) ALDH1A1PKMRXFP1LMNAL3MBTL1
SCHEMBL6727872 0.84 OPRM1 (0.38) ALDH1A1MAPTKMT2AF10GAA
SCHEMBL6737775 0.84 GAA (0.42) ALDH1A1PKMRXFP1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 ALDH1A1 1316/4885PKM 1374/4885RXFP1 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.